AVE 0.00% 0.2¢ avecho biotechnology limited

Voveran TPM vs voltaren, page-2

  1. 34,916 Posts.
    lightbulb Created with Sketch. 480
    I think the $117K of revenue out of this commercialisation in full year 2014 gives you a fair indication of what's happening out there. Sounds like yet another failed product as far as POH is concerned. I wouldn't be hanging my hat on this potential.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.